<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732485</url>
  </required_header>
  <id_info>
    <org_study_id>07-389</org_study_id>
    <secondary_id>SHC 08-GAL-006</secondary_id>
    <nct_id>NCT00732485</nct_id>
  </id_info>
  <brief_title>Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate</brief_title>
  <official_title>The Role of Mitochondrial Oxidation on Insulin Resistance in Burn Patients Treated With Fenofibrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major burn injury causes significant insulin resistance on glucose and protein metabolism&#xD;
      that persists for up to 6 months after the acute injury&#xD;
&#xD;
      This project proposes to answer the following questions:&#xD;
&#xD;
        1. Will fenofibrate given to burn patients with insulin resistance restore their insulin&#xD;
           sensitivity?&#xD;
&#xD;
        2. What is the relationship between mitochondrial dysfunction in muscle tissue as the&#xD;
           causative mechanism of burn related insulin resistance?&#xD;
&#xD;
        3. To what extent will the restored insulin sensitivity affect glucose and protein&#xD;
           metabolism in muscle, regenerating wounds and the liver, i.e. ameliorate burn related&#xD;
           hyperglycemia and protein catabolism?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following specific hypotheses will be investigated:&#xD;
&#xD;
        1. Following severe burn injury in human patients the mitochondrial fat oxidation capacity&#xD;
           is decreased in muscle. This is associated with a corresponding progression in the&#xD;
           severity of the resistance to the action of insulin on glucose disposal and protein&#xD;
           synthesis and breakdown in muscle, regenerating wound and liver.&#xD;
&#xD;
        2. Fatty acids, or their active intracellular products (e.g., DAG, acyl-CoenzymeA (Co-A),&#xD;
           or acylcarnitine), are the direct inhibitors of insulin action, rather than tissue&#xD;
           triglycerides (TG) itself. In other words, impaired mitochondrial fatty acid oxidation&#xD;
           is the mechanism that causes altered lipid metabolism that ultimately contributes to&#xD;
           insulin resistance.&#xD;
&#xD;
        3. Accumulation of active fatty acid products, such as DAG, acyl-CoA, or acylcarnitine&#xD;
           esters in muscle cells is due to the rate of uptake of plasma free fatty acid (FFA)&#xD;
           exceeding the rate of oxidation within muscle due principally to a reduced capacity of&#xD;
           mitochondria to oxidize fatty acids.&#xD;
&#xD;
        4. Decreased insulin sensitivity in muscle is related to impaired insulin signaling. This&#xD;
           will be reflected by increased activity of protein kinase C (PKC). Because PKC is&#xD;
           thought to exert its regulatory effect primarily on either tyrosine kinase activity on&#xD;
           the insulin receptor or downstream kinase insulin receptor substrate (IRS)&#xD;
           phosphorylation, these elements of the insulin signaling cascade will be decreased. In&#xD;
           turn, elements of insulin signaling related to the response of muscle glucose (PI3&#xD;
           kinase) and protein (P70S6k) metabolism will be reduced. We propose that increased&#xD;
           tissue PKC activity will be associated with increased tissue concentration of DAG,&#xD;
           acyl-CoA, or acylcarnitine.&#xD;
&#xD;
        5. Treatment of patients with the peroxisome proliferator-activated receptor (PPAR) alpha&#xD;
           agonist fenofibrate will improve mitochondrial capacity to oxidize fatty acids.&#xD;
&#xD;
        6. Insulin sensitivity in muscle, skin and liver in terms of both glucose and protein&#xD;
           metabolism will be improved by fenofibrate treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Principal Investigator Changed&#xD;
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity on glucose and protein metabolism</measure>
    <time_frame>From admission to burn unit to 6 months post burn</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic glucose homeostasis</measure>
    <time_frame>Admission to 6 months post burn</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle protein balance</measure>
    <time_frame>Admission to 6 months post burn</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound protein balance</measure>
    <time_frame>Admission to 6 months post burn</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Burn</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn</description>
    <arm_group_label>Fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo, sugar pill, from admission to 6 months post burn</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 7 years old with burns covering 40% or more of body surface who are&#xD;
             admitted to the Shriners Hospital for Children, Galveston, Texas&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal liver and kidney function,&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  Diabetes mellitus,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical Branch, Galveston</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Cree MG, Zwetsloot JJ, Herndon DN, Qian T, Morio B, Fram R, Sanford AP, Aarsland A, Wolfe RR. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg. 2007 Feb;245(2):214-21.</citation>
    <PMID>17245174</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burn injury</keyword>
  <keyword>Fenofibrate</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Mitochondrial function</keyword>
  <keyword>Fat oxidation</keyword>
  <keyword>PPAR</keyword>
  <keyword>Protein</keyword>
  <keyword>Glucose</keyword>
  <keyword>Wound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

